The pharmaceutical industry has seen recent innovations in treating depression, notably with the emergence of Spravato (esketamine).
Spravato is the S-enantiomer form of ketamine, a racemic mixture of two enantiomers. As for their administration, Spravato is an intranasal formulation, meaning it is administered through the nose, while ketamine can be administered intravenously, intramuscularly, or orally. Additionally, Spravato has obtained FDA approval for treatment-resistant depression. In contrast, ketamine has yet to secure this status and has been widely used off-label for depression and other mental health conditions.
Other differences between Spravato and ketamine include dosage and monitoring requirements. The dose of Spravato used in treatment is lower than ketamine, which may result in fewer side effects for some patients. However, Spravato must be administered in a clinical setting, with patients monitored for at least two hours post-treatment. On the other hand, ketamine can be administered in both clinical and non-clinical settings.
Lone Peak Psychiatry considers that the launch of Spravato has significantly addressed the unmet needs of depression management. Industry professionals are optimistic that it will revolutionize care for those with treatment-resistant depression. Its unique administration style, dosage options, and FDA-approved status amplify this hope.
About Lone Peak Psychiatry
Lone Peak Psychiatry is a Ketamine clinic located in Murray, UT. We offer Ketamine treatments to those suffering from Mental Health disorders such as Depression, Anxiety, PTSD, and OCD. Our mission is to help those struggling to find relief and regain their lives.
This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.
